| Companies sponsors |
Servier |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Bowel Cancer UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
Bayer (regorafenib) CAU signed -participating |
| |
Bristol Myers Squibb (ipilimumab, nivolumab) CAU not signed (not participating) |
| |
Hospira UK (irinotecan, fluorouracil, oxaliplatin, raltitrexed) CAU not signed (not participating) |
| |
Medac GmbH (fluorouracil, folinic acid, irinotecan, oxaliplatin) CAU not signed (not participating) |
| |
Merck Serono (cetuximab) CAU signed- participating |
| |
Pierre Fabre (encorafenib) CAU not signed (not participating) |
| |
Pfizer (bevacizumab, irinotecan) CAU signed- participating |
| |
Ranbaxy (irinotecan, oxaliplatin) CAU not signed (not participating) |
| |
Seacross Pharmaceuticals (irinotecan, oxaliplatin) CAU not signed (not participating) |
| |
Celltrion Healthcare (bevacizumab) CAU not signed (not participating) |
| |
Organon Pharma (bevacizumab) CAU not signed (not participating) |
| |
Roche (bevacizumab) CAU signed- participating |
| |
Thornton & Ross (bevacizumab) CAU not signed (not participating) |
| |
Zentiva (bevacizumab) CAU signed- Participating |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
| |
National Institute for Health Research |